



Conserved Glu-47 and Lys-50 residues are critical for UDP-*N*-acetylglucosamine/UMP antiport activity of the mouse Golgi-associated transporter Slc35a3

Received for publication, April 13, 2019, and in revised form, May 9, 2019. Published, Papers in Press, May 22, 2019, DOI 10.1074/jbc.RA119.008827

M. Agustina Toscanini^{‡1,2}, M. Belén Favarolo^{‡1,3}, F. Luis Gonzalez Flecha^{‡4}, Berit Ebert^{§5}, Carsten Rautengarten[§], and Luis M. Bredeston^{‡4,6}

From the [‡]Departamento de Química Biológica-IQUIFIB, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires-CONICET, Ciudad Autónoma de Buenos Aires, Junín 956 (1113), Argentina and the [§]School of BioSciences, University of Melbourne, Melbourne, Victoria 3010, Australia

Edited by Gerald W. Hart

Nucleotide sugar transporters (NSTs) regulate the flux of activated sugars from the cytosol into the lumen of the Golgi apparatus where glycosyltransferases use them for the modification of proteins, lipids, and proteoglycans. It has been well-established that NSTs are antiporters that exchange nucleotide sugars with the respective nucleoside monophosphate. Nevertheless, information about the molecular basis of ligand recognition and transport is scarce. Here, using topology predictors, cysteine-scanning mutagenesis, expression of GFP-tagged protein variants, and phenotypic complementation of the yeast strain KI3, we identified residues involved in the activity of a mouse UDP-GlcNAc transporter, murine solute carrier family 35 member A3 (mSlc35a3). We specifically focused on the putative transmembrane helix 2 (TMH2) and observed that cells expressing E47C or K50C mSlc35a3 variants had lower levels of GlcNAc-containing glycoconjugates than WT cells, indicating impaired UDP-GlcNAc transport activity of these two variants. A conservative substitution analysis revealed that single or double substitutions of Glu-47 and Lys-50 do not restore GlcNAc glycoconjugates. Analysis of mSlc35a3 and its genetic variants reconstituted into proteoliposomes disclosed the following: (i) all variants act as UDP-GlcNAc/UMP antiporters; (ii) conservative substitutions (E47D, E47Q, K50R, or K50H) impair UDP-GlcNAc uptake; and (iii) substitutions of Glu-47 and Lys-50 dramatically alter kinetic parameters, consistent with a

critical role of these two residues in mSlc35a3 function. A bioinformatics analysis revealed that an EXXK motif in TMH2 is highly conserved across SLC35 A subfamily members, and a 3D-homology model predicted that Glu-47 and Lys-50 are facing the central cavity of the protein.

Nucleotide sugars play a key role as precursors for the biosynthesis of glycoconjugates in the secretory pathway. These activated sugar donors serve as substrates for glycosyltransferases. Although they are on the cytoplasmic side of the endoplasmic reticulum (ER),⁷ they allow the attachment of sugars to dolichol phosphate to form glycosylated lipid precursors, and within the Golgi lumen, they are required for the glycosylation of proteins, lipids, and proteoglycans. To enable the latter and to overcome the subcellular partitioning of substrates and enzymes, nucleotide sugars are required to be imported from the cytoplasm into the Golgi lumen by specific membrane proteins, the so-called nucleotide sugar transporters (NSTs) (1, 2). The physiological relevance of this transport process is well-documented from unicellular (3) to multicellular organisms (4, 5), whereas mutations that impair NST function are associated with severe developmental phenotypes.

Based on biochemical (6) and genetic approaches (7), an antiport mechanism exchanging a nucleotide sugar with the corresponding nucleoside monophosphate has been proposed for NST function (2). The cloning, expression, and functional characterization of more than 60 NSTs from diverse species revealed that some of them act as monospecific transporters, whereas others turned out to have the capability of transporting multiple substrates in a competitive or simultaneous process (8–17).

Based on sequence analyses, mammalian NSTs were classified as members of the solute carrier 35 family (SLC35), together with 3'-phosphoadenosine-5'-phosphosulfate (18) and ATP transporters (19). However, of the 24 members of the SLC35 subfamilies A–G, only half have been experimentally characterized in different species, including humans (18). In

This work was supported by the National Research Council (CONICET, Argentina) Grant PIP-11220090100811, and University of Buenos Aires Travel Award (to L. M. B.). The authors declare that they have no conflicts of interest with the contents of this article.

This article contains Figs. S1–S5 and Tables S1 and S2.

¹ Both authors contributed equally to this work.

² Present address: Dept. de Biotecnología, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, CABA, 1113 Argentina.

³ Present address: Instituto de Biología Celular y Neurociencias “Prof. E. De Robertis,” Facultad de Medicina, Universidad de Buenos Aires-CONICET, CABA, 1121 Argentina.

⁴ Career Investigators of the National Research Council (CONICET, Argentina).

⁵ Supported by Australian Research Council Future Fellowship FT160100276, Discovery Grant DP180102630 and Mizutani Foundation for Glycoscience Grant 18-0237.

⁶ To whom correspondence should be addressed: Dept. de Química Biológica-IQUIFIB, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires-CONICET, Ciudad Autónoma de Buenos Aires, Junín 956 (1113), Argentina. Tel.: 5411-52874794; Fax: 5411-49625457; E-mail: bredeston@qb.ffyb.uba.ar.

⁷ The abbreviations used are: ER, endoplasmic reticulum; NST, nucleotide sugar transporter; TMH2, transmembrane helix 2; PDB, Protein Data Bank; 3-PGA, 3-phosphoglycerate; CL, cysteine-less; CMP-SA, CMP-sialic acid; DMT, drug/metabolite transporter.

humans, mutations of five NSTs of the SLC35 family with diverse substrate specificities, namely A1 (20, 21), A2 (22, 23), A3 (24), C1 (25–27), and D1 (28), are linked to congenital disorders of glycosylation that cause diverse severe neurological and skeletal anomalies.

Among the Slc35 family, subfamily A is the most thoroughly characterized. For three of its five members substrate specificities have been identified. A1, A2, and A3 are specific for CMP-sialic acid (CMP-SA) (29), UDP-galactose (UDP-Gal) (30), and UDP-GlcNAc (31), respectively. Studies determining the topology of the mouse CMP-SA transporter Slc35a1, using an epitope-insertion technique, indicated a 10-transmembrane protein with the N and C termini facing the cytosol (32). Furthermore, studies using chimeric mutants of A1 and A2 (33, 34), as well as mutational analyses (35, 36), identified transmembrane domains and residues critically important for the recognition of CMP-SA as a substrate.

Another well-characterized member of the subfamily A, Slc35a3, is a Golgi-resident UDP-GlcNAc transporter present in multicellular organisms with high-sequence conservation from worms (4) to mammals (31). A mutation (V180F) in the predicted transmembrane helix 6 of Slc35a3 causes complex vertebral malformation in cattle (37), a lethal autosomal-recessive defect. Recently, mutations of the human SLC35A3 ortholog have been associated with autism spectrum disorder, epilepsy, and skeletal malformations. Affected patients carry variants containing single amino acid changes or truncated proteins (24, 38–40). Gene silencing of SLC35A3 in mammalian cell lines affects the biosynthesis of highly branched N-glycans and keratan sulfate (41). Furthermore, it has been reported that the UDP-Gal (Slc35a2) and UDP-GlcNAc (Slc35a3) transporters can associate with acetylglucosaminyltransferases (42) to form complexes, an observation that may be related to the sequential addition of the sugars GlcNAc, galactose, and sialic acid during the processing of glycoproteins.

Since the first observation of nucleotide sugar uptake into mouse liver microsomes (43), substantial efforts have been made to understand NST function and physiological relevance (1). However, information about the relationship between structure and function is still scarce, and mechanisms underpinning nucleotide sugar transport at the molecular level remain largely unknown. Recently, the first crystal structure of NST was determined. The obtained 3D model of the yeast Vrg4 GDP-mannose transporter provided crucial information to start understanding the molecular mechanisms of nucleotide sugar import into the Golgi (44).

Here, we report a simple approach to test the *in vivo* function of NSTs. This approach combined bioinformatic analyses, cysteine-scanning mutagenesis, GFP-based detection of protein expression, and phenotypic complementation of yeast mutants that allowed us to identify amino acid residues required for UDP-GlcNAc transport activity of the mouse Slc35a3. A detailed investigation of the transmembrane helix 2 from Slc35a3 identified two critical residues, glutamic acid 47 and lysine 50. Conservative replacements combined with *in vivo* and *in vitro* activity assays confirmed the significance of both residues for transport activity.

Results

Expression and transport activity of the mouse SLC35A3 assessed in yeast using a whole-cell fluorescence approach

Mouse Slc35a3 (mSLC35A3), a protein consisting of 326 amino acids, shares between 95 and 96% sequence identity with four mammalian SLC35A3 variants, which previously have been experimentally characterized as Golgi-localized UDP-GlcNAc transporters (31, 37, 45, 46). To confirm the substrate specificity of mSlc35a3, K13 cells, a mutant strain of the yeast *Kluyveromyces lactis* lacking a functional UDP-GlcNAc transporter, were transformed with either the empty vector (plasmid pE4) or pE4mSLC35A3. Subsequently, the cells were incubated with GSII lectin conjugated to FITC (GSII-FITC), which specifically binds GlcNAc-containing glycoconjugates. Only the suspension of K13 cells transformed with pE4mSLC35A3 showed fluorescence levels similar to that of WT K18 cells, carrying the functional UDP-GlcNAc transporter, indicating that they recovered the ability to bind the lectin GSII-FITC (Fig. 1A, dark gray bars). In this *in vivo* system, UDP-GlcNAc transport activity, mediated by mSLC35A3, is indirectly evaluated through the restoration of GlcNAc-containing glycoconjugates at the surface of K13 cells. This implicates at least three steps as follows: the restoration of the import of UDP-GlcNAc into the lumen of the Golgi apparatus through expression of an active transporter; the synthesis of GlcNAc glycoconjugates by specific luminal transferases; and an appropriate membrane cell-sorting process of these products (47).

One aim of this work was to generate a collection of mutants and conveniently test their expression while avoiding time-consuming methods. To achieve this, the sequence of the green fluorescent protein (GFP) was fused to mSlc35a3. As shown in Fig. 1C, perinuclear fluorescence in K13 cells transformed with mSLC35A3-GFP can be visualized by confocal microscopy, consistent with the expression of mSlc35a3-GFP in the secretory pathway. Subsequent spectrofluorimetric measurements of the cell suspensions showed an increase in GFP fluorescence compared with cells transformed with the empty vector (pE4) or pE4mSlc35a3 (Fig. 1A, white bars). Heating the cell suspensions for 1 min at 90 °C reduced the fluorescence signal of mSlc35a3-GFP-expressing cells to background levels of the control cells transformed with the empty vector. This is most likely due to the irreversible denaturation of the GFP fusion protein (Fig. 1, A, gray bars, and C).

The results presented in Fig. 1A indicate that fusing GFP to mSlc35a3 did not significantly alter its transport capacity (Fig. 1B) as revealed by the binding of the lectin. Next, the V180F mutation that had been shown to impair transport activity of the bovine Slc35a3 transporter (37) was introduced into the mouse SLC35A3 sequence, and subsequently the Slc35a3 mutant was expressed as GFP fusion in K13 cells. Although the expression level of the mutated variant was higher than the WT protein (Fig. 1A, white bars), cells expressing the V180F variant bound less than 25% of the GSII-FITC lectin compared with cells expressing mSlc35a3-GFP (Fig. 1B). This indicates a substantial decrease in UDP-GlcNAc transport activity. Taken together, our results suggest that this approach, based on heterologous expression of GFP-tagged proteins combined with GSII-FITC lectin recognition of GlcNAc glycoconjugates, can

Role of charged residues for nucleotide sugar transport




Figure 1. Expression of mSLC35A3 and phenotypic complementation of Kl3 cells. Kl3 cells were grown in YPD media, and Kl3 cells transformed with plasmid pE4 (*Mock*), pE4-mSLC35A3 (*WT*), pE4-mSLC35A3-GFP (*WT-GFP*), or pE4-V180F-GFP (*V180F-GFP*) were grown in $-$ Ura media to an OD = 2.0. **A**, GFP fluorescence of the cell suspension was measured before (*white bars*) and after incubation at 90 °C for 1 min (*light gray bars*). The heated cells were incubated with GSII-FITC lectin, and fluorescence associated with cell suspensions was measured (*dark gray bars*). Fluorescence measurements were normalized to OD₆₀₀ of the suspension and expressed as fluorescence arbitrary units (a.u.)/OD₆₀₀. **B**, fluorescence of GSII-FITC bound to Kl3 cells expressing mSLC35A3 and variants. Background fluorescence of mock cells was subtracted, and values are expressed as a percentage of WT-GFP. *Error bars* represent the mean and S.E. of three independent replicates. **C**, confocal microscopy fluorescence of Kl3 cells transformed with pE4 (*Mock*) or pE4-mSLC35A3GFP (*WT-GFP*) plasmids. *Scale bar*, 4 μ m.

successfully be employed to evaluate the expression and activity of mSLC35A3.

Topology analysis of mSlc35a3

To identify amino acid residues relevant for transport activity, we first analyzed the primary amino acid sequence of mSlc35a3, using the topology predictors TOPCONS, MEMSAT-SVM, HMMTOP, and TMHMM. As summarized in [Table S1](#), 8–10 transmembrane helices (TMHs) were predicted for mSLC35A3. The data obtained from the different prediction programs varied the most on TMHs 3 and 4, whereas TMHs 1–2 and 5–10 were predicted by all methods used, with slight extension differences ([Fig. S1](#)). Similar results were obtained for other well-characterized UDP-GlcNAc transporters from different species, including *Homo sapiens* and *Caenorhabditis elegans* as well as for different members of subfamily A, e.g. mouse Slc35a1, the only NST for which the topology has been experimentally determined (32). Based on this information, a 10-transmembrane helical model was proposed as an initial working hypothesis for mSlc35a3 ([Fig. 2](#)). Given the even number of TMHs and the positive inside rule (48), we conclude that both the N and C termini would be oriented to the cytoplasmic side. A general analysis of the amino acid distribution in the model showed an accumulation of charged and polar residues in luminal and cytoplasmic loops, whereas within the transmembrane helices hydrophobic residues prevailed. A detailed assessment of the transmembrane helices in the model revealed that five TMHs (1, 3, 4, 6, and 9) were enriched in amino acids with polar characteristics, whereas only three charged residues were identified, namely

Glu-47 and Lys-50 located in TMH2 and Lys-120 in TMH4 ([Table 1](#)).

Cys-scanning mutagenesis of transmembrane helix 2

As shown in [Fig. 2](#), the mSlc35a3 amino acid sequence contains three cysteine residues: Cys-54 in TMH2, Cys-64 in the loop between TMH2 and TMH3, and Cys-184 in TMH6. To generate a collection of cysteine-unique mutants, we first produced a cysteine-less variant (CL). Therefore, mSlc35a3 variant containing substitutions corresponding to C54S/C64S/C184S was generated and fused to GFP. The expression level of CL-GFP in Kl3 cells was similar to that of WT-GFP ([Fig. S2](#)). After incubation with GSII-FITC, cells bound close to 80% of the lectin compared with cells expressing the WT protein ([Fig. 3](#)). As assessed by phenotypic complementation of Kl3 cells, all cysteine replacements were well-tolerated by the protein, indicating that they are not essential for transport activity and concluding that the CL mutant is functionally active *in vivo*.

Based on the bioinformatic results obtained for the mSlc35a3 sequence ([Fig. 2](#) and [Table 1](#)), further experimental analysis focused on the putative TMH2. Notably, TMH2, which was predicted by all membrane topology programs used in this study, is highly hydrophobic and contains two charged amino acids embedded in the membrane. Charged and polar residues in transmembrane domains of transport proteins are usually involved in the binding of hydrophilic substrates, domain interactions, or conformational changes as part of the transport mechanism (49). Consequently, the corresponding codon of each amino acid between leucine 38 to lysine 60 was substituted by a cysteine codon using CL as a backbone, and a collection of




Figure 2. Ten transmembrane helices model of mSlc35a3. Amino acids with distinctive physicochemical properties are labeled as follows: *green* (nonpolar: Gly, Ala, Val, Cys, Pro, Leu, Ile, Met, Trp, and Phe), *orange* (polar: Ser, Thr, Tyr, Asn, and Gln), *blue* (positively charged: Lys, Arg, and His), and *red* (negatively charged: Asp and Glu). The three cysteines 54, 64, and 184 are highlighted in *yellow*.

Table 1

Polar and charged amino acid residues located within the predicted transmembrane helices of mSlc35a3. Charged residues are highlighted in bold.

Transmembrane helices	Residue and no.
1	Ser-9, Gln-16, Thr-17, Thr-18, Ser-19, Thr-23
2	Glu-47, Lys-50
3	Ser-91, Tyr-94, Thr-95, Gln-97, Asn-98, Asn-99, Tyr-102
4	Gln-118, Lys-120 , Thr-123, Thr-124, Ser-128
5	Ser-143
6	Thr-182, Ser-186, Ser-187
7	Ser-217
8	Thr-245, Gln-252
9	Thr-275, Ser-276, Ser-278, Ser-282, Thr-283, Ser-286, Tyr-287
10	Thr-310




Figure 3. Analysis of cysteine-unique mutants by phenotypic complementation of K13 cells. Cells were grown in $-Ura$ media, heated, and incubated with GSII-FITC 1 h at room temperature. The fluorescence of GSII-FITC bound to K13 cells was measured and expressed as percentage of the WT-GFP value. *Error bars* represent the mean and S.E. of three independent replicates.

23 cysteine-unique mutants fused to GFP was generated. As shown in Fig. S2, all K13 transformants exhibited GFP fluorescence higher than cells transformed with the empty vector, which decreased to mock background levels after heat treatment. Incubation with GSII-FITC showed that most of the cells expressing cysteine-unique mutants bound the lectin, with fluorescence intensity values higher than 40% of the WT, consistent with a restoration of the UDP-GlcNAc import into the lumen of the Golgi apparatus (Fig. 3). The only exceptions were mutants A42C, V44C, E47C, and K50C, which revealed a specific binding of GSII-FITC lower than 20% that of WT cells, indicative of a severe impairment of transport activity.

Phenotypic complementation of K13 cells requires the synthesis and incorporation of an active form of mSlc35a3 in membranes of the secretory pathway (ER/Golgi apparatus). To exclude incorrect membrane insertion or organelle localization as a cause for the inability of these mutants to transport UDP-GlcNAc, two approaches were undertaken. First, localization of the C-terminally GFP-tagged mutants was evaluated by confocal microscopy. K13 cells transformed with a plasmid carrying different mutants and CL were grown to an $OD_{600} = 2$, and the cellular localization of the GFP fluorescence signal was analyzed. Similar to CL-GFP-expressing cells, perinuclear fluorescence was observed for all mutants tested, a pattern consistent with expression in the secretory pathway (Fig. 4A). Second, membranes were isolated by ultracentrifugation, and proteins abundant in these membrane fractions were separated by SDS-PAGE and analyzed by in-gel fluorescence. As shown in Fig. 4B, a predominant band for all mutants with mobility close to the 60-kDa marker was observed. This is consistent with the calculated molecular mass of 55 kDa corresponding to the fusion protein mSlc35a3-GFP (Fig. 4). In agreement with the microscopy data, but not with whole-cell fluorescence results (Fig. S2), the intensity of the main band of mutant 44 was slightly lower compared with the others. Taken together, these




Figure 4. Localization and membrane insertion of inactive mutants. *A*, cells transformed with the empty vector pE4 (*Mock*), pE4-CL-GFP, and pE4 containing the mutated versions A42C, V44C, E47C, and K50C were grown in $-$ Ura media to an OD = 2, and GFP fluorescence was visualized by confocal microscopy. Scale bar, 4 μ m. *B*, proteins associated with membranes were obtained by ultracentrifugation and separated by SDS-PAGE, and in-gel fluorescence was determined. The lane numbers on the gel correspond to the follows: lane 1, mock; lane 2, CL; lane 3, A42C; lane 4, V44C; lane 5, E47C; lane 6, K50C; and lane 7, mass marker.

results strongly suggest that all variants were well-integrated into the membranes of the secretory pathway, but in an inactive form.

Analysis of involvement of Glu-47 and Lys-50 residues in mSLC35A3-mediated transport through conservative substitution analysis

To study the importance of residues Ala-42, Val-44, Glu-47, and Lys-50 for the function of mSlc35a3, conservative replacements were made using the WT sequence as backbone. K13 cells transformed with the mutant alleles A42V, A42G, V44A, V44I, or V44L fused to GFP showed fluorescence levels similar to those observed for well-expressed proteins (*white bars*, Fig. S3) and values of GSII-FITC binding between 50 and 140% compared with K13 cells expressing the WT transporter (Fig. 5). The reduced binding of GSII-FITC in K13 cells expressing A42G (50%), but not in A42V (90%), suggests the importance of a lateral group, absent in the small and hydrophilic amino acid glycine. In contrast, cells expressing all Val-44 mutants exhibited an increased abundance of glycoconjugates,




Figure 5. Analysis of single and double mutants of mSlc35a3. K13 cells were transformed with the empty vector pE4, pE4-WT-GFP, or pE4 carrying single and double mutants of mSlc35a3 fused to GFP. Cells were grown in $-$ Ura media, isolated, heated for 1 min at 90 $^{\circ}$ C, and incubated with GSII-FITC for 1 h at room temperature. Fluorescence of the cell suspensions was measured and expressed as a percentage of WT-GFP. Error bars represent the mean and S.E. of three independent replicates.

suggesting that the changes of V44A, V44I, or V44L improve the function of mSlc35a3 and increase the concentration of luminal UDP-GlcNAc. These results indicate that conservative substitutions of Ala-42 or Val-44 are well-tolerated as revealed by the *in vivo* transport activity. However, our data further suggest that cysteine replacements in these positions are incompatible with the function of mSlc35a3.

To assess the role of glutamic acid 47 for mSLC35A3 activity, mutations to alanine (E47A), aspartic acid (E47D), or glutamine (E47Q) were generated, and K13 cells were transformed with the corresponding variants. As shown in Fig. S3, expression of the mutant E47A was not detectable, whereas E47D and E47Q were expressed at similar levels compared with the WT protein. The *in vivo* activity was assessed by incubation of K13 transformants with GSII-FITC lectin. Cells expressing the E47D mutant bound 47% of the lectin compared with control cells transformed with the WT protein. By contrast, the substitution E47Q completely abolished the biosynthesis of GlcNAc glycoconjugates and showed no binding. The significance of lysine 50 was examined by substituting Lys-50 with alanine (K50A), histidine (K50H), or arginine (K50R). K13 cells were transformed with the corresponding mutant variants, and expression was monitored by whole-cell GFP fluorescence. As is shown in Fig. S3, no expression was detectable for K50H, whereas the K50A and K50R variants were expressed at similar levels to those of the WT protein. Upon incubation of K13 cells expressing the K50R mutant with GSII-FITC, low levels of GlcNAc were detected, suggesting severely impaired transport activity.

To explore a possible interaction between both charged amino acids, double mutants were generated and expressed in K13 cells (Fig. S3). To elucidate whether a charge imbalance in the individual mutations (E47C or K50C) caused the impairment in transport activity, both charges were neutralized (E47A/K50A). To analyze whether their specific positions in TMH2 are of particular relevance, both residues were interchanged (E47K/K50E). Finally, a mutant containing substitu-




Figure 6. *In vitro* activities of mSlc35a3 and variants. *A*, proteoliposomes containing WT or mutants, preloaded with 30 mM UMP, were incubated with UDP-GlcNAc at a concentration of 50 μM for the indicated time points at 37 °C. UDP-GlcNAc uptakes are expressed in nanomoles normalized to the total protein content in proteoliposomes (four independent replicates). *B*, proteoliposomes containing WT and mutants, preloaded with 30 mM UMP, were incubated with UDP-GlcNAc at varying concentrations (0.5–200 μM) for 30 s at 37 °C. Activity values were normalized to the GFP fluorescence in proteoliposome preparations. For each mSLC35A3 variant, 10 data points (four independent replicates) were acquired, and a hyperbolic function was fitted by nonlinear regression using the Prism 7 application. Best fit kinetic parameters are shown in Table 2 and are represented as the mean \pm S.E.

tions of the residues that lead to simultaneous changes in length but conservation of the original charge (E47D/K50R) was generated. As shown in Fig. 5, neutralization of the charge or interchange of the position disrupts the production of GlcNAc glycoconjugates on the surface of K13 cells transformed with the corresponding plasmids. K13 cells expressing the E47D/K50R mutant bound less than 20% of the lectin compared with cells expressing the WT protein, suggesting an additive effect of the corresponding individual mutations.

Glu-47 and Lys-50 are critical for UDP-GlcNAc/UMP exchange activity of mSlc35a3

Phenotypic complementation of K13 cells was used as an efficient way to screen and identify relevant residues. However, limited information could be obtained about the specific properties of the mSlc35a3 variants. To study the UDP-GlcNAc transport properties of mSLC35A3 and the effect of the mutations E47D, E47Q, K50R, and K50H in detail, the WT protein as well as the variants were heterologously expressed in *Saccharomyces cerevisiae*. Membrane proteins were reconstituted into liposomes, and the corresponding proteoliposome preparations, preloaded with UMP, were incubated with UDP-GlcNAc, and nucleotide sugar uptake was evaluated by MS. UDP-GlcNAc uptake was saturable in a time- and concentration-dependent manner (Fig. 6, *A* and *B*). Determinations of the kinetic parameters of UDP-GlcNAc transport activity mediated by the WT mSLC35A3 revealed a K_m of 22 μM and V_{max} of 894 nM s^{-1} (Table 2). In contrast, proteoliposomes containing the corresponding mutant variants E47D, E47Q, K50R, or K50H showed UDP-GlcNAc accumulation over time with variable levels between 1 and 10% compared with the WT (Fig. 6*B*). Velocities were dramatically affected in Glu-47 and Lys-50 substitutions with values close to 10 and 1% of WT mSlc35a3. The apparent affinities of the variants for UDP-GlcNAc showed a decrease for all mutants except for E47D (Table 2).

Table 2

Kinetic parameters of UDP-GlcNAc transport mediated by mSlc35a3 and selected mutants

	WT	E47D	E47Q	K50R	K50H
K_m (μM)	22 \pm 3	7 \pm 1	108 \pm 46	63 \pm 17	307 \pm 152
V_{max} (nM s^{-1})	894 \pm 29	114 \pm 4	72 \pm 15	7 \pm 1	3 \pm 1

EXXK motif is specific to subfamily A members and conserved among species

A multiple alignment generated from the putative TMH2 amino acid sequences of mSlc35a3 and other members of the mouse SLC35 family revealed that the EXXK motif containing Glu-47 and Lys-50 is present only in subfamily A (Fig. 7), indicating uniqueness of the motif and possibly providing distinct structural/functional properties. In addition, the motif is found in characterized NSTs across a variety of species ranging from unicellular organisms like *Entamoeba histolytica* (50) and yeast (51) to worms (4), plants (52), and mammals (29, 45). This suggests an early occurrence of this subfamily in eukaryotes and an adaptation to transport diverse substrates during evolution.

Interactions between TMH2/TMH7 and TMH2/TMH8 were predicted by coevolution studies of amino acid residues

Evolutionary constraints on the function and structure of proteins are reflected in conserved interactions between pairs or groups of amino acids (53). To evaluate possible interactions involving residues of TMH2 in the context of the whole protein, the mSlc35a3 sequence was analyzed using the algorithm EVfold_membrane. This algorithm extracts coevolution patterns from multiple sequence alignments using an entropy maximization approach (54). The scoring of evolutionarily constrained pairs, many reflecting interactions between residues close in space, suggests that residues from TMH2 interact with residues of TMH7 and TMH8. As shown in the contact map (Fig. S4) from 330 evolutionary couplings, specifically, the five pairs Val-44/Leu-221, Ile-51/Phe-214, Ile-51/Ser-217, Phe-48/Ser-217, and Ile-55/Ile-210 are predicted to interact between TMH2 and TMH7, and the two pairs Ala-53/Ala-253 and Leu-

Role of charged residues for nucleotide sugar transport

```
SLC35F5      MALG---IVILLLVDIWVASSELT SYVFTQYNFLIWKPWQRQC TRGRGKPAAFFADAE
SLC35F1      -AEDFHAN--TPVFQSF----LNYILLFLVYTTTTLAVRQGEENLLAILRR-----
SLC35F2      -----TPMLQSF----INCYLLFLVYTTMLAFQSGSDNLLLEILRR-----
SLC35F3      TFKTFD----APFTLTWFATNWNFLFFFLYYAGHVCKSTEQSMKQRYRE-----CC
SLC35F4      TYKNFY----CPFFMTWFSTNWNIMFFPVYISGHLATAQEKQSPIKKFRE-----CS
SLC35B4      ARTHPGCG-----NIVTFAQFLFTAVEGFLFEA-----N-----L
SLC35B3      FSVE---GFKPYG-----WYLTLVQFAFYSVFGLIE-L-----Q-----L
SLC35B1      TRGKYGEGPKQETFFA--LTLVFIQCVINAMFAKILIQ-----F-----F
SLC35B2      MTGSYGATATSPGEHFTDSQFLVLMNRVLALVVAGLYCV-----L
SLC35A5      SAN--EEN---KYD-YLPTTVNVCSELMKLLILCILLVSLCVIKKE-DHQSRH-LR---C
SLC35A4      LALCHVDG---RVP-FRPSSAVLLTBLTKLLLLCAFSLLVGVQWTP-----
SLC35A1      TRT-TA-----EEL-YFSTTAVCITEVTKLLISVGLL-AKETGSLGRFKAS-LS---E
SLC35A2      ART-LP-----GDR-FFATTAVVMAEVIKGLTCLLLLFAQKRGNVKHLVLF-LH---E
SLC35A3      SRT-LKEE---GPR-YLSSTAVVVAEFTKIMACIFLVYKDSKCSVRALNRV-LH---D
SLC35D3      LISRY-----QFSF--LTLVQCLTSSTAALSLELLRRL-----GL-----IAVPPFG
SLC35D1      VLTNY-----RFPS--SLCVGLGQMVATVAVLVVWGKTL-----RV-----VKFPDFD
SLC35D2      LLTTY-----GFPS--PIVLGIGQMATTIMILYVFKLN-----KI-----IHFPDFD
SLC35E1      -----A---GLPPLLRWRVPPAPPVS-----GPGGPHPASGP-----
SLC35E2      ILSLL-----E---GEPSMLGAVQMLSTTLIG-CVKIFVPCCLYQHKTRL-----
SLC35C1      LLDSP-----SLQLDTPIFVTFYQCLVTSLLCKGLSTLATCCP-GMVDFPTL---NLD
SLC35C2      LTKSF-----HFPLEMT-MLHL---AVIFLFSALSRLVQCS-SHKARVVLSTWTDYL
SLC35E3      IYVHH-----GFPNMSLTLVHF---VVTWLG-----LYICQ-KL-----DYL
```

Figure 7. Multiple sequence alignment of mSLC35 members. The sequences of the predicted members of family SLC35 from mice were aligned using Clustal Omega. Residues corresponding to TMH2 of mSLC35A3 are *underlined*. The conserved residues of the motif EXXK are colored in *red* (Glu) and *blue* (Lys).

49/Val-248 are predicted to interact between TMH2 and TMH8. Our results revealed no coevolution pairs between TMH7 and TMH8 suggesting a localization on opposite sides of TMH2. For the highly conserved residues Glu-47 and Lys-50, no interaction with residues of other TMHs were predicted.

Finally, the 3D structure of the protein was computed using EVfold_membrane, based only on the predicted residue contacts and restrictions imposed by topology (54). The resulting model, shown in Fig. S5, contains 10 TMHs with an arrangement resembling the structure of members of the drug/metabolite transporter (DMT) superfamily that have been crystallized so far (44, 55, 56).

Homology model of mSlc35a3

A homology model of mSlc35a3 was generated using the Phyre2 Protein Fold Recognition Server (57). The model was built on the basis of the structure of Vrg4 (PDB code 5OGE), and the quality of the model was tested using the structure-validated web server Molprobit (58). A comparison of the homology model (Fig. 8) with the model obtained using coevolutionary information (Fig. S5) shows that they are highly similar. The resulting models contain 10 TMHs folded in two with a central cavity limited by TMH2–4 and TMH6–9, whereas TMH5 and TMH10 outside this core structure appear as a zipper. Residues Glu-47 and Lys-50 seem to be oriented to the same side of TMH2 facing the central cavity of the protein (Fig. 8B).

Discussion

In this work, a combination of bioinformatic and experimental approaches identified two charged residues, Glu-47 and Lys-50, as potentially important for mouse Slc35a3 function. Conservative substitutions of these amino acids resulted in a severe impairment of mSlc35a3 function with a dramatic reduction in UDP-GlcNAc/UMP exchange, thereby highlighting the critical role of Glu-47 and Lys-50. Shortening the length of the side chain in E47D and elimination of the charge in E47Q affected the UDP-GlcNAc transport capacity of mSlc35a3 (Figs. 5

and 6), indicating the requirement of the negative charge and side-chain length, likely involved in interactions during the UDP-GlcNAc/UMP exchange. Even more dramatic effects were caused by substitutions of Lys-50, which almost completely inactivated UDP-GlcNAc transport activity, both *in vivo* and *in vitro* (Figs. 5 and 6).

An analysis of the topology of the protein indicates that residues that maintain close spatial proximity are embedded in the highly hydrophobic center of TMH2. Charge balance, relative position, or intrahelix interactions of Glu-47 and Lys-50 were explored by generating the double mutants E47A/K50A, E47K/K50E, and E47D/K50R. For all double mutants, the phenotypic complementation assay indicated a very low flux of UDP-GlcNAc into the Golgi lumen suggesting that the relative position of the charges in the TMH2 are critical for mSlc35a3 function.

Sequence comparisons of members of the mouse SLC35 family showed that the motif EXXK present in TMH2 is specific to members of SLC35 subfamily A (Fig. 7). The identified substrates for Slc35a1, -a2, and -a3 (CMP-SA, UDP-Gal, and UDP-GlcNAc, respectively) are highly diverse in terms of their nucleotide and sugar residues (29–31). Therefore, it is difficult to directly associate these charged amino acids of the consensus motif with an initial ligand recognition on the cytosolic side of the transporter. However, the corresponding nucleotides are pyrimidines and have a common structure that could be recognized. One hypothesis could be that the negatively charged phosphate group of the nucleotide sugar or the nucleoside monophosphate could interact with these charged residues during ligand recognition. The alteration of the kinetic parameters in the mutants (Table 2) is compatible with the coordination of one or both ligands.

Moreover, the participation of the two charged residues of the consensus motif could be related to a secondary event that is common to all members of subfamily A, e.g. the helix–helix interactions or conformational changes as part of an alternating access mechanism. The coevolution analysis of mSlc35a3 predicted an interaction between TMH2 and TMH7 via five con-




Figure 8. Homology-based model of mSlc35a3. The homology model was generated as was described under “Experimental procedures.” *A*, ribbon representation of the structure, viewed from the plane of the membrane (left) and luminal side (right). *B*, ribbon representation of TMH2, TMH7, and TMH8.

tact points (Fig. S4). Particularly, three of those involved residues Phe-48 (with Ser-217 residue) and Ile-51 (with Phe-214 and Ser-217 residues) that are located right next to Glu-47 and Lys-50 in the sequence of TMH2. Studies on chimeric proteins Slc35a1 and -a2 showed that a swap of the amino acid sequences corresponding to TMH2, TMH3, and TMH7 from Slc35a1 to Slc35a2 conferred CMP-SA specificity in addition to its originally identified substrate UDP-Gal. Moreover, the introduction of Tyr-214 and Ser-216 residues from Slc35a1 at the same position into Slc35a2-TMH7 revealed that they are critically important for the recognition of CMP-SA. Altogether, based on these results it can be assumed that certain residues of TMH7 could be important for the recognition of the substrate, whereas others may be involved in interactions with residues of TMH2 as part of the coupling mechanism.

High-resolution crystal structures have been obtained for three other members of the DMT superfamily, to which the NSTs belong. The structural analyses of SnYddG, a bacterial aromatic amino acid exporter (55), GsGPT, a eukaryotic or 3-phosphoglycerate (3-PGA)/P_i translocator (56), and Vrg4, the GDP-mannose (GDP-Man) transporter from yeast (44), revealed 10 TMHs folded into the N- and a C-terminal halves (55). The structural results for GsGPT, bound to P_i or 3-PGA, showed that the phosphate moieties (P-O₂, O₃, and O₄) of P_i or 3-PGA are recognized by ionic bonds with Lys-204 (TMH4) and Lys-362/Arg-363 (TMH9) and a hydrogen bond with Tyr-339 (TMH8). The glycerate group of 3-PGA specifically interacts via an ionic bond with His-185 (TMH3), a hydrogen bond with Tyr-339 (TMH8), and hydrophobic contacts with Thr-188, Phe-192 (TMH3), and Phe-263 (TMH6). Mutational anal-

yses and molecular dynamics simulations confirmed the significance of these residues. They revealed that Glu-207 (TMH4), the only conserved acidic residue in the positively charged binding pockets, is critical as a molecular switch, interacting with Lys-204 (TMH4) or Arg-363 (TMH9) (59). Sequence comparisons of subfamily members with distinct sugar-phosphate specificities suggest conservation of these residues that interact with the phosphate moieties and variability within the residues that interact with the sugar, hence determining the specificity.

The structure of the yeast GDP-Man transporter Vrg4 was resolved in the apoprotein and GDP-Man-bound forms (44). The results showed that the nucleotide and sugar are accommodated within separate binding pockets. The nucleotide pocket is composed of side chains of the residues Asn-220 and Asn-221 located within TMH7 and Ser-266 (TMH8) that interact with guanine, and Tyr-28 (TMH1), Ser-269 (TMH8) and Tyr-281 (TMH9) that interact with the ribose group. Met-35 (TMH1) interacts with the first phosphate and Lys-289 (TMH9) interacts with the β -phosphate and the glycosidic-bond oxygen. Tyr-114, located within TMH4, is involved in sugar binding via the C2 hydroxyl group on the mannose ring. Based on the structural and mutational analyses, the authors proposed an alternating-access mechanism (44). The interaction of conserved residues from the two inverted repeats TMH1–5 and TMH6–10, Ser-32 (TMH1), Lys-289 (TMH9), Asn-191 (TMH6), and Lys-118 (TMH4), are formed and broken during the transport cycle.

Fig. 8 shows the homology model for mSlc35a3 based on the crystallographic structure of Vrg4. Remarkably, this model is very similar to the coevolution model (Fig. S5). Both models

mutant using the WT cDNA as template and the corresponding primers (E47Dr, E47Qr, E47Ar, E47Cr, K50Rr, E47K/K50Er, E47D/K50Rr, V44Ar, V44Lr, and V44Ir). The identity of the cloned fragments was confirmed by DNA sequencing.

Yeast strain, transformation, and growth media

For transformation of the *K. lactis* mutant 3 (Kl3, Mata, uraA, mnn2-2, arg2⁻ K⁺, pKD1⁺) a lithium acetate/PEG method was utilized (69). Cells were grown in complete YPD media (0.75% yeast extract, 1.13% peptone, 2.2% dextrose), and transformants were selected by their ability to grow at 28 °C in the absence of uracil (–Ura media) on plates containing 0.67% yeast nitrogen base with ammonium sulfate without amino acids (YNB), 0.08% complete supplemented medium minus Ura (Ura⁻), 2.0% dextrose, and 2.0% agar. WT *K. lactis* cells (Kl8), used as a positive control for the UDP-GlcNAc transporter complementation assays, were grown at 28 °C in YPD media.

Cell surface labeling of *K. lactis* with GSII–FITC

To assay the activity of the mouse Slc35a3 variants, Kl3 cells transformed with the corresponding pE4 vector (31) were grown overnight in 5 ml of synthetic uracil dropout media to an OD₆₀₀ = 1–2 as described earlier (31). Cells were collected by centrifugation and washed with Solution I (150 mM NaCl, 0.5 mM CaCl₂). Cell density was estimated at 600 nm (OD₆₀₀), and an aliquot, corresponding to 2 units of OD₆₀₀, was isolated by centrifugation and subsequently resuspended in 200 μl of solution I. GFP fluorescence (excitation, 485 nm/emission, 514 nm) was measured before and after incubation at 90 °C for 1 min to estimate the expression of the corresponding mSLC35A3–GFP variants (WT or mutants). After the 90 °C incubation step, the cells were harvested by centrifugation; the supernatant was discarded; and the pellet was incubated in the presence of 25 μl of GSII–FITC (EY Laboratories) labeling solution (3 parts of lectin + 1 part 150 mM NaCl, 4 mM CaCl₂) for 1 h at 25 °C. After this step, the cells were pelleted, washed with 1.5 ml of solution I, and resuspended in 200 μl of solution I before the GFP fluorescence was determined. Fluorescence measurements were normalized to the OD₆₀₀.

Confocal microscopy of yeast expressing mSlc35a3–GFP

Kl3 cells transformed with pE4 and pE4–MmSLC35A3–GFP (WT or mutants) were mounted on YSB buffer and imaged using an Olympus Fluoview FV1000 spectral laser-scanning confocal microscope with a ×60 oil immersion lens using 473 nm excitation. GFP fluorescence emission was collected between 500 and 550 nm.

Analysis of the membrane integration of the mSlc35a3–GFP fusions using in-gel fluorescence analysis

Total membrane fractions were prepared using glass beads to disrupt the cell pellets derived from 10-ml yeast cultures (OD₆₀₀ = 1–2) in YSB buffer (10% glycerol, 5 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 50 mM Tris–HCl, pH 7.6). The suspensions were centrifuged at 2,000 × g followed by centrifugation of the supernatants at 100,000 × g for 1 h. Resulting membrane pellets were resuspended in YSB buffer prior to protein separation by electrophoresis on 12% SDS-poly-

acrylamide gels (70). Gels were scanned using a Storm 840 molecular imager (Amersham Biosciences) to determine GFP fluorescence.

In vitro transport assay

UDP-*N*-acetyl- α -D-glucosamine (UDP-GlcNAc) was obtained from Sigma. The yeast strain INVSci (Thermo Fisher Scientific) was transformed using the S.c. EasyCompTM transformation kit (Thermo Fisher Scientific). Yeast growth, cell disruption, membrane isolation, membrane protein reconstitution into liposomes, transport activity assays, and MS were performed as described previously in detail (12). Kinetic parameters were calculated by nonlinear regression using the Prism 7 application (GraphPad Software, La Jolla, CA).

Coevolution analysis

The coevolution analysis of residues pairs of MmSlc35a3 was performed using the EV coupling web interface (<http://evfold.org/evfold-web/evfold.do>)⁸ (54).

Homology modeling

The homology model of mSlc35a3 was generated using the Phyre2 Protein Fold Recognition Server (<http://www.sbg.bio.ic.ac.uk/phyre2>) (57). The model was built on the basis of the structure of Vrg4 (PDB code 5OGE). Model quality was tested using the structure-validate web server Molprobit (<http://molprobit.biochem.duke.edu>)⁸ (58).

Author contributions—L. M. B. conceptualization; M. A. T., M. B. F., B. E., C. R., F. L. G. F., and L. M. B. data curation; M. A. T., M. B. F., B. E., C. R., F. L. G. F., and L. M. B. formal analysis; L. M. B. Supervision; B. E. and L. M. B. Funding acquisition; M. A. T., M. B. F., B. E., C. R., F. L. G. F., and L. M. B. investigation; M. A. T., M. B. F., B. E., C. R., F. L. G. F., and L. M. B. methodology; L. M. B. writing-original draft; L. M. B. project administration; M. A. T., M. B. F., B. E., C. R., F. L. G. F., and L. M. B. writing-review and editing.

Acknowledgments—We thank Drs. Javier Santos, Hugo Adamo, and Pablo Schwarzbaum for critical reading of the manuscript and Dr. Gerardo Corradi for technical assistance obtaining the confocal microscopy images.

Addendum—During the review process of this manuscript, new information about the structure of a plant CMP-sialic acid transporter, CSTZM, was made available (Nji, E., Gulati, A., Qureshi, A. A., Coincon, M., and Drew, D. (2019) Structural basis for the delivery of activated sialic acid into Golgi for sialylation. *bioRxiv* CrossRef). This work has shown that residues Glu-42 and Lys-45 on TMH2 are critical for the coordination of the ligand CMP. The coordinates of the structures corresponding to CMP bound CSTZM (PDB code 611R) and apo CSTZM (PDB code 611Z) have been deposited in the Protein Data Bank.

References

- Hirschberg, C. B. (2018) My journey in the discovery of nucleotide sugar transporters of the Golgi apparatus. *J. Biol. Chem.* **293**, 12653–12662 CrossRef Medline

⁸Please note that the JBC is not responsible for the long-term archiving and maintenance of this site or any other third party hosted site.

Role of charged residues for nucleotide sugar transport

- Hirschberg, C. B., Robbins, P. W., and Abeijon, C. (1998) Transporters of nucleotide sugars, ATP, and nucleotide sulfate in the endoplasmic reticulum and Golgi apparatus. *Annu. Rev. Biochem.* **67**, 49–69 [CrossRef](#) [Medline](#)
- Caffaro, C. E., Koshy, A. A., Liu, L., Zeiner, G. M., Hirschberg, C. B., and Boothroyd, J. C. (2013) A nucleotide sugar transporter involved in glycosylation of the *Toxoplasma* tissue cyst wall is required for efficient persistence of bradyzoites. *PLoS Pathog.* **9**, e1003331 [CrossRef](#) [Medline](#)
- Caffaro, C. E., Hirschberg, C. B., and Berninsone, P. M. (2007) Functional redundancy between two *Caenorhabditis elegans* nucleotide sugar transporters with a novel transport mechanism. *J. Biol. Chem.* **282**, 27970–27975 [CrossRef](#) [Medline](#)
- Liu, L., and Hirschberg, C. B. (2013) Developmental diseases caused by impaired nucleotide sugar transporters. *Glycoconj. J.* **30**, 5–10 [CrossRef](#) [Medline](#)
- Capasso, J. M., and Hirschberg, C. B. (1984) Mechanisms of glycosylation and sulfation in the Golgi apparatus: evidence for nucleotide sugar/nucleoside monophosphate and nucleotide sulfate/nucleoside monophosphate antiports in the Golgi apparatus membrane. *Proc. Natl. Acad. Sci. U.S.A.* **81**, 7051–7055 [CrossRef](#) [Medline](#)
- Berninsone, P., Miret, J. J., and Hirschberg, C. B. (1994) The Golgi guanosine diphosphatase is required for transport of GDP-mannose into the lumen of *Saccharomyces cerevisiae* Golgi vesicles. *J. Biol. Chem.* **269**, 207–211 [Medline](#)
- Caffaro, C. E., Hirschberg, C. B., and Berninsone, P. M. (2006) Independent and simultaneous translocation of two substrates by a nucleotide sugar transporter. *Proc. Natl. Acad. Sci. U.S.A.* **103**, 16176–16181 [CrossRef](#) [Medline](#)
- Rautengarten, C., Ebert, B., Moreno, I., Temple, H., Herter, T., Link, B., Doñas-Cofré, D., Moreno, A., Saéz-Aguayo, S., Blanco, F., Mortimer, J. C., Schultink, A., Reiter, W. D., Dupree, P., Pauly, M., et al. (2014) The Golgi localized bifunctional UDP-rhamnose/UDP-galactose transporter family of *Arabidopsis*. *Proc. Natl. Acad. Sci. U.S.A.* **111**, 11563–11568 [CrossRef](#) [Medline](#)
- Bredston, L. M., Marino-Buslje, C., Mattera, V. S., Buzzi, L. I., Parodi, A. J., and D'Alessio, C. (2017) The conundrum of UDP-Glc entrance into the yeast ER lumen. *Glycobiology* **27**, 64–79 [CrossRef](#) [Medline](#)
- Ebert, B., Rautengarten, C., Guo, X., Xiong, G., Stonebloom, S., Smith-Moritz, A. M., Herter, T., Chan, L. J., Adams, P. D., Petzold, C. J., Pauly, M., Willats, W. G., Heazlewood, J. L., and Scheller, H. V. (2015) Identification and characterization of a Golgi-localized UDP-xylose transporter family from *Arabidopsis*. *Plant Cell* **27**, 1218–1227 [CrossRef](#) [Medline](#)
- Rautengarten, C., Ebert, B., Liu, L., Stonebloom, S., Smith-Moritz, A. M., Pauly, M., Orellana, A., Scheller, H. V., and Heazlewood, J. L. (2016) The *Arabidopsis* Golgi-localized GDP-L-fucose transporter is required for plant development. *Nat. Commun.* **7**, 12119 [CrossRef](#) [Medline](#)
- Saez-Aguayo, S., Rautengarten, C., Temple, H., Sanhueza, D., Ejsmentewicz, T., Sandoval-Ibañez, O., Doñas, D., Parra-Rojas, J. P., Ebert, B., Lehner, A., Mollet, J. C., Dupree, P., Scheller, H. V., Heazlewood, J. L., Reyes, F. C., and Orellana, A. (2017) UMAT1 is a Golgi-localized UDP-uronic acid transporter that modulates the polysaccharide composition of *Arabidopsis* seed mucilage. *Plant Cell* **29**, 129–143 [CrossRef](#) [Medline](#)
- Rautengarten, C., Birdseye, D., Pattathil, S., McFarlane, H. E., Saez-Aguayo, S., Orellana, A., Persson, S., Hahn, M. G., Scheller, H. V., Heazlewood, J. L., and Ebert, B. (2017) The elaborate route for UDP-arabinose delivery into the Golgi of plants. *Proc. Natl. Acad. Sci. U.S.A.* **114**, 4261–4266 [CrossRef](#) [Medline](#)
- Li, L. X., Rautengarten, C., Heazlewood, J. L., and Doering, T. L. (2018) Xylose donor transport is critical for fungal virulence. *PLoS Pathog.* **14**, e1006765 [CrossRef](#) [Medline](#)
- Li, L. X., Rautengarten, C., Heazlewood, J. L., and Doering, T. L. (2018) UDP-glucuronic acid transport is required for virulence of *Cryptococcus neoformans*. *MBio* **9**, e02319-17 [Medline](#)
- Ebert, B., Rautengarten, C., McFarlane, H. E., Rupasinghe, T., Zeng, W., Ford, K., Scheller, H. V., Bacic, A., Roessner, U., Persson, S., and Heazlewood, J. L. (2018) A Golgi UDP-GlcNAc transporter delivers substrates for N-linked glycans and sphingolipids. *Nat. Plants* **4**, 792–801 [CrossRef](#) [Medline](#)
- Ashikov, A., Routier, F., Fuhlrott, J., Helmus, Y., Wild, M., Gerardy-Schahn, R., and Bakker, H. (2005) The human solute carrier gene SLC35B4 encodes a bifunctional nucleotide sugar transporter with specificity for UDP-xylose and UDP-N-acetylglucosamine. *J. Biol. Chem.* **280**, 27230–27235 [CrossRef](#) [Medline](#)
- Klein, M. C., Zimmermann, K., Schorr, S., Landini, M., Klemens, P. A. W., Altensell, J., Jung, M., Krause, E., Nguyen, D., Helms, V., Rettig, J., Fecher-Trost, C., Cavalié, A., Hoth, M., Bogeski, I., et al. (2018) AXER is an ATP/ADP exchanger in the membrane of the endoplasmic reticulum. *Nat. Commun.* **9**, 3489 [CrossRef](#) [Medline](#)
- Martinez-Duncker, I., Dupré, T., Piller, V., Piller, F., Candelier, J. J., Trichet, C., Tchernia, G., Oriol, R., and Mollicone, R. (2005) Genetic complementation reveals a novel human congenital disorder of glycosylation of type II, due to inactivation of the Golgi CMP-sialic acid transporter. *Blood* **105**, 2671–2676 [CrossRef](#) [Medline](#)
- Mohamed, M., Ashikov, A., Guillard, M., Robben, J. H., Schmidt, S., van den Heuvel, B., de Brouwer, A. P., Gerardy-Schahn, R., Deen, P. M., Wevers, R. A., Lefeber, D. J., and Morava, E. (2013) Intellectual disability and bleeding diathesis due to deficient CMP-sialic acid transport. *Neurology* **81**, 681–687 [CrossRef](#) [Medline](#)
- Ng, B. G., Buckingham, K. J., Raymond, K., Kircher, M., Turner, E. H., He, M., Smith, J. D., Eroshkin, A., Szybowska, M., Losfeld, M. E., Chong, J. X., Kozenko, M., Li, C., Patterson, M. C., Gilbert, R. D., et al. (2013) Mosaicism of the UDP-galactose transporter SLC35A2 causes a congenital disorder of glycosylation. *Am. J. Hum. Genet.* **92**, 632–636 [CrossRef](#) [Medline](#)
- Kodera, H., Nakamura, K., Osaka, H., Maegaki, Y., Haginoya, K., Mizumoto, S., Kato, M., Okamoto, N., Iai, M., Kondo, Y., Nishiyama, K., Tsurusaki, Y., Nakashima, M., Miyake, N., Hayasaka, K., et al. (2013) *De novo* mutations in SLC35A2 encoding a UDP-galactose transporter cause early-onset epileptic encephalopathy. *Hum. Mutat.* **34**, 1708–1714 [CrossRef](#) [Medline](#)
- Edvardson, S., Ashikov, A., J alas, C., Sturiale, L., Shaag, A., Fedick, A., Treff, N. R., Garozzo, D., Gerardy-Schahn, R., and Elpeleg, O. (2013) Mutations in SLC35A3 cause autism spectrum disorder, epilepsy and arthropropysis. *J. Med. Genet.* **50**, 733–739 [CrossRef](#) [Medline](#)
- Lübke, T., Marquardt, T., Etzioni, A., Hartmann, E., von Figura, K., and Körner, C. (2001) Complementation cloning identifies CDG-IIc, a new type of congenital disorders of glycosylation, as a GDP-fucose transporter deficiency. *Nat. Genet.* **28**, 73–76 [CrossRef](#) [Medline](#)
- Lühn, K., Wild, M. K., Eckhardt, M., Gerardy-Schahn, R., and Vestweber, D. (2001) The gene defective in leukocyte adhesion deficiency II encodes a putative GDP-fucose transporter. *Nat. Genet.* **28**, 69–72 [CrossRef](#) [Medline](#)
- Dauber, A., Ercan, A., Lee, J., James, P., Jacobs, P. P., Ashline, D. J., Wang, S. R., Miller, T., Hirschhorn, J. N., Nigrovic, P. A., and Sackstein, R. (2014) Congenital disorder of fucosylation type 2c (LADII) presenting with short stature and developmental delay with minimal adhesion defect. *Hum. Mol. Genet.* **23**, 2880–2887 [CrossRef](#) [Medline](#)
- Furuichi, T., Kayserili, H., Hiraoka, S., Nishimura, G., Ohashi, H., Alanay, Y., Lerena, J. C., Aslanger, A. D., Koseki, H., Cohn, D. H., Superti-Furga, A., Unger, S., and Ikegawa, S. (2009) Identification of loss-of-function mutations of SLC35D1 in patients with Schneckbecken dysplasia, but not with other severe spondylodysplastic dysplasias group diseases. *J. Med. Genet.* **46**, 562–568 [CrossRef](#) [Medline](#)
- Eckhardt, M., Mühlhoff, M., Bethe, A., and Gerardy-Schahn, R. (1996) Expression cloning of the Golgi CMP-sialic acid transporter. *Proc. Natl. Acad. Sci. U.S.A.* **93**, 7572–7576 [CrossRef](#) [Medline](#)
- Miura, N., Ishida, N., Hoshino, M., Yamauchi, M., Hara, T., Ayusawa, D., and Kawakita, M. (1996) Human UDP-galactose translocator: molecular cloning of a complementary DNA that complements the genetic defect of a mutant cell line deficient in UDP-galactose translocator. *J. Biochem.* **120**, 236–241 [CrossRef](#) [Medline](#)
- Guillen, E., Abeijon, C., and Hirschberg, C. B. (1998) Mammalian Golgi apparatus UDP-N-acetylglucosamine transporter: molecular cloning by phenotypic correction of a yeast mutant. *Proc. Natl. Acad. Sci. U.S.A.* **95**, 7888–7892 [CrossRef](#) [Medline](#)

32. Eckhardt, M., Gotza, B., and Gerardy-Schahn, R. (1999) Membrane topology of the mammalian CMP-sialic acid transporter. *J. Biol. Chem.* **274**, 8779–8787 [CrossRef Medline](#)
33. Aoki, K., Ishida, N., and Kawakita, M. (2003) Substrate recognition by nucleotide sugar transporters: further characterization of substrate recognition regions by analyses of UDP-galactose/CMP-sialic acid transporter chimeras and biochemical analysis of the substrate specificity of parental and chimeric transporters. *J. Biol. Chem.* **278**, 22887–22893 [CrossRef Medline](#)
34. Aoki, K., Ishida, N., and Kawakita, M. (2001) Substrate recognition by UDP-galactose and CMP-sialic acid transporters. Different sets of transmembrane helices are utilized for the specific recognition of UDP-galactose and CMP-sialic acid. *J. Biol. Chem.* **276**, 21555–21561 [CrossRef Medline](#)
35. Takeshima-Futagami, T., Sakaguchi, M., Uehara, E., Aoki, K., Ishida, N., Sanai, Y., Sugahara, Y., and Kawakita, M. (2012) Amino acid residues important for CMP-sialic acid recognition by the CMP-sialic acid transporter: analysis of the substrate specificity of UDP-galactose/CMP-sialic acid transporter chimeras. *Glycobiology* **22**, 1731–1740 [CrossRef Medline](#)
36. Maggioni, A., von Itzstein, M., Rodríguez Guzman, I. B., Ashikov, A., Stephens, A. S., Haselhorst, T., and Tiralongo, J. (2013) Characterisation of CMP-sialic acid transporter substrate recognition. *Chembiochem* **14**, 1936–1942 [CrossRef Medline](#)
37. Thomsen, B., Horn, P., Panitz, F., Bendixen, E., Petersen, A. H., Holm, L. E., Nielsen, V. H., Agerholm, J. S., Arnbjerg, J., and Bendixen, C. (2006) A missense mutation in the bovine SLC35A3 gene, encoding a UDP-N-acetylglucosamine transporter, causes complex vertebral malformation. *Genome Res.* **16**, 97–105 [CrossRef Medline](#)
38. Marini, C., Hardies, K., Pisano, T., May, P., Weckhuysen, S., Cellini, E., Suls, A., Mei, D., Balling, R., Jonghe, P. D., Helbig, I., Garozzo, D., EuroEPINOMICS consortium AR working group, and Guerrini, R. (2017) Recessive mutations in SLC35A3 cause early onset epileptic encephalopathy with skeletal defects. *Am. J. Med. Genet. A* **173**, 1119–1123 [CrossRef Medline](#)
39. Edmondson, A. C., Bedoukian, E. C., Deardorff, M. A., McDonald-McGinn, D. M., Li, X., He, M., and Zackai, E. H. (2017) A human case of SLC35A3-related skeletal dysplasia. *Am. J. Med. Genet. A* **173**, 2758–2762 [CrossRef Medline](#)
40. Bruneel, A., Cholet, S., Drouin-Garraud, V., Jacquemont, M. L., Cano, A., Mégarbané, A., Ruel, C., Cheillan, D., Dupré, T., Vuillaumier-Barrot, S., Seta, N., and Fenaille, F. (2018) Complementarity of electrophoretic, mass spectrometric, and gene sequencing techniques for the diagnosis and characterization of congenital disorders of glycosylation. *Electrophoresis* **39**, 3123–3132 [CrossRef Medline](#)
41. Maszczak-Senczek, D., Sosicka, P., Olczak, T., Jakimowicz, P., Majkowski, M., and Olczak, M. (2013) UDP-N-acetylglucosamine transporter (SLC35A3) regulates biosynthesis of highly branched N-glycans and keratan sulfate. *J. Biol. Chem.* **288**, 21850–21860 [CrossRef Medline](#)
42. Maszczak-Senczek, D., Sosicka, P., Kaczmarek, B., Majkowski, M., Luzarowski, M., Olczak, T., and Olczak, M. (2015) UDP-galactose (SLC35A2) and UDP-N-acetylglucosamine (SLC35A3) transporters form glycosylation-related complexes with mannoside acetylglucosaminyl-transferases (Mgats). *J. Biol. Chem.* **290**, 15475–15486 [CrossRef Medline](#)
43. Carey, D. J., Sommers, L. W., and Hirschberg, C. B. (1980) CMP-N-acetylneuraminic acid: isolation from and penetration into mouse liver microsomes. *Cell* **19**, 597–605 [CrossRef Medline](#)
44. Parker, J. L., and Newstead, S. (2017) Structural basis of nucleotide sugar transport across the Golgi membrane. *Nature* **551**, 521–524 [CrossRef Medline](#)
45. Ishida, N., Yoshioka, S., Chiba, Y., Takeuchi, M., and Kawakita, M. (1999) Molecular cloning and functional expression of the human Golgi UDP-N-acetylglucosamine transporter. *J. Biochem.* **126**, 68–77 [CrossRef Medline](#)
46. Andersen, P. K., Veng, L., Juul-Madsen, H. R., Vingborg, R. K., Bendixen, C., and Thomsen, B. (2007) Gene expression profiling, chromosome assignment and mutational analysis of the porcine Golgi-resident UDP-N-acetylglucosamine transporter SLC35A3. *Mol. Membr. Biol.* **24**, 519–530 [CrossRef Medline](#)
47. Abeijon, C., Robbins, P. W., and Hirschberg, C. B. (1996) Molecular cloning of the Golgi apparatus uridine diphosphate-N-acetylglucosamine transporter from *Kluyveromyces lactis*. *Proc. Natl. Acad. Sci. U.S.A.* **93**, 5963–5968 [CrossRef Medline](#)
48. Heijne, G. (1986) The distribution of positively charged residues in bacterial inner membrane proteins correlates with the trans-membrane topology. *EMBO J.* **5**, 3021–3027 [CrossRef Medline](#)
49. Illergård, K., Kauko, A., and Elofsson, A. (2011) Why are polar residues within the membrane core evolutionary conserved? *Proteins* **79**, 79–91 [CrossRef Medline](#)
50. Bredeston, L. M., Caffaro, C. E., Samuelson, J., and Hirschberg, C. B. (2005) Golgi and endoplasmic reticulum functions take place in different subcellular compartments of *Entamoeba histolytica*. *J. Biol. Chem.* **280**, 32168–32176 [CrossRef Medline](#)
51. Tabuchi, M., Tanaka, N., Iwahara, S., and Takegawa, K. (1997) The *Schizosaccharomyces pombe* gms1+ gene encodes a UDP-galactose transporter homologue required for protein galactosylation. *Biochem. Biophys. Res. Commun.* **232**, 121–125 [CrossRef Medline](#)
52. Temple, H., Saez-Aguayo, S., Reyes, F. C., and Orellana, A. (2016) The inside and outside: topological issues in plant cell wall biosynthesis and the roles of nucleotide sugar transporters. *Glycobiology* **26**, 913–925 [CrossRef Medline](#)
53. Marks, D. S., Hopf, T. A., and Sander, C. (2012) Protein structure prediction from sequence variation. *Nat. Biotechnol.* **30**, 1072–1080 [CrossRef Medline](#)
54. Hopf, T. A., Colwell, L. J., Sheridan, R., Rost, B., Sander, C., and Marks, D. S. (2012) Three-dimensional structures of membrane proteins from genomic sequencing. *Cell* **149**, 1607–1621 [CrossRef Medline](#)
55. Tsuchiya, H., Doki, S., Takemoto, M., Ikuta, T., Higuchi, T., Fukui, K., Usuda, Y., Tabuchi, E., Nagatoishi, S., Tsumoto, K., Nishizawa, T., Ito, K., Dohmae, N., Ishitani, R., and Nureki, O. (2016) Structural basis for amino acid export by DMT superfamily transporter YddG. *Nature* **534**, 417–420 [CrossRef Medline](#)
56. Lee, Y., Nishizawa, T., Takemoto, M., Kumazaki, K., Yamashita, K., Hirata, K., Minoda, A., Nagatoishi, S., Tsumoto, K., Ishitani, R., and Nureki, O. (2017) Structure of the triose-phosphate/phosphate translocator reveals the basis of substrate specificity. *Nat. Plants* **3**, 825–832 [CrossRef Medline](#)
57. Kelley, L. A., Mezulis, S., Yates, C. M., Wass, M. N., and Sternberg, M. J. (2015) The Phyre2 web portal for protein modeling, prediction and analysis. *Nat. Protoc.* **10**, 845–858 [CrossRef Medline](#)
58. Chen, V. B., Arendall, W. B., III, Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., and Richardson, D. C. (2010) MolProbity: all-atom structure validation for macromolecular crystallography. *Acta Crystallogr. D Biol. Crystallogr.* **66**, 12–21 [CrossRef Medline](#)
59. Takemoto, M., Lee, Y., Ishitani, R., and Nureki, O. (2018) Free energy landscape for the entire transport cycle of triose-phosphate/phosphate translocator. *Structure* **26**, 1284–1296.e4 [CrossRef Medline](#)
60. Jack, D. L., Yang, N. M., and Saier, M. H., Jr. (2001) The drug/metabolite transporter superfamily. *Eur. J. Biochem.* **268**, 3620–3639 [CrossRef Medline](#)
61. Tsirigos, K. D., Peters, C., Shu, N., Käll, L., and Elofsson, A. (2015) The TOPCONS web server for consensus prediction of membrane protein topology and signal peptides. *Nucleic Acids Res.* **43**, W401–W407 [CrossRef Medline](#)
62. Nugent, T., and Jones, D. T. (2009) Transmembrane protein topology prediction using support vector machines. *BMC Bioinformatics* **10**, 159 [CrossRef Medline](#)
63. Tusnády, G. E., and Simon, I. (2001) The HMMTOP transmembrane topology prediction server. *Bioinformatics* **17**, 849–850 [CrossRef Medline](#)
64. Krogh, A., Larsson, B., von Heijne, G., and Sonnhammer, E. L. (2001) Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes. *J. Mol. Biol.* **305**, 567–580 [CrossRef Medline](#)
65. Sievers, F., and Higgins, D. G. (2018) Clustal Omega for making accurate alignments of many protein sequences. *Protein Sci.* **27**, 135–145 [CrossRef Medline](#)

Role of charged residues for nucleotide sugar transport

66. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
67. Newstead, S., Kim, H., von Heijne, G., Iwata, S., and Drew, D. (2007) High-throughput fluorescent-based optimization of eukaryotic membrane protein overexpression and purification in *Saccharomyces cerevisiae*. *Proc. Natl. Acad. Sci. U.S.A.* **104**, 13936–13941 [CrossRef](#) [Medline](#)
68. Sarkar, G., and Sommer, S. S. (1990) The “megaprimer” method of site-directed mutagenesis. *BioTechniques* **8**, 404–407 [Medline](#)
69. Elble, R. (1992) A simple and efficient procedure for transformation of yeasts. *BioTechniques* **13**, 18–20 [Medline](#)
70. Laemmli, U. K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* **227**, 680–685 [CrossRef](#) [Medline](#)